Filed reports

22 reports · Mar 2021 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report type	Reports	Facts	Periods
Half YearBundesanzeiger	6	669	Jun 2021 to Jun 2026
Q1Bundesanzeiger	6	218	Mar 2021 to Mar 2026
AnnualBundesanzeiger	5	295	Dec 2021 to Dec 2025
Q3Bundesanzeiger	5	216	Sep 2021 to Sep 2025

Period	Type	Period end	Published	Facts	Source
FY2026 Q2	half year	Jun 30, 2026	Jun 30, 2026	204	Open
FY2026 Q1	q1	Mar 31, 2026	Mar 31, 2026	84	Open
FY2025	annual	Dec 31, 2025	Dec 31, 2025	64	Open
FY2025 Q3	q3	Sep 30, 2025	Sep 30, 2025	50	Open
FY2025 Q2	half year	Jun 30, 2025	Jun 30, 2025	96	Open
FY2025 Q1	q1	Mar 31, 2025	Mar 31, 2025	27	Open
FY2024	annual	Dec 31, 2024	Dec 31, 2024	58	Open
FY2024 Q3	q3	Sep 30, 2024	Nov 12, 2024	12	Open
FY2024 Q2	half year	Jun 30, 2024	Jun 30, 2024	98	Open
FY2024 Q1	q1	Mar 31, 2024	Mar 31, 2024	28	Open
FY2023	annual	Dec 31, 2023	Dec 31, 2023	61	Open
FY2023 Q3	q3	Sep 30, 2023	Sep 30, 2023	52	Open

Financial data

179 concepts · 1,398 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Revenue32 · Mar 2021 to Jun 2026
Cost of Goods and Services Sold31 · Mar 2021 to Jun 2026
EBIT131 · Mar 2021 to Jun 2026
Financial expenses31 · Mar 2021 to Jun 2026
Financial income31 · Mar 2021 to Jun 2026
General administration expenses31 · Mar 2021 to Jun 2026
Gross Profit31 · Mar 2021 to Jun 2026
Income after income taxes31 · Mar 2021 to Jun 2026
of which attributable to Bayer AG stockholders31 · Mar 2021 to Jun 2026
Other operating expenses31 · Mar 2021 to Jun 2026
Other operating income31 · Mar 2021 to Jun 2026
Pretax Income31 · Mar 2021 to Jun 2026
R&D Expense31 · Mar 2021 to Jun 2026
Selling and Marketing Expense31 · Mar 2021 to Jun 2026
Income Tax Expense (Benefit)30 · Mar 2021 to Jun 2026
of which attributable to noncontrolling interest29 · Jun 2021 to Jun 2026
Financial result28 · Mar 2021 to Dec 2025
EPS (Basic)26 · Jun 2021 to Jun 2026
EPS (Diluted)26 · Jun 2021 to Jun 2026
Depreciation, amortization and impairment losses / loss reversals23 · Mar 2021 to Sep 2025
Equity-method income (loss)23 · Mar 2021 to Sep 2025
Net income (from continuing and discontinued operations)23 · Mar 2021 to Sep 2025
Personnel expenses (including pension expenses)23 · Mar 2021 to Dec 2025
Earnings per share1 from continuing and discontinued operations (€)19 · Sep 2021 to Sep 2025

EBITDA before special items¹43 · Jun 2021 to Jun 2026
Revenue43 · Jun 2021 to Jun 2026
Intersegment sales35 · Jun 2021 to Jun 2026
Depreciation, amortization, impairment losses / loss reversals31 · Jun 2021 to Jun 2025
Net sales (external)31 · Jun 2021 to Jun 2025
EBIT¹24 · Jun 2021 to Jun 2026
Operating Cash Flow15 · Jun 2021 to Jun 2026
Net sales (total)10 · Jun 2026
Europe / Middle East / Africa6 · Sep 2024
Depreciation, amortization, impairment losses/loss reversals5 · Jun 2026
EBIT before special items¹4 · Jun 2026
EBITDA¹4 · Jun 2026
EBITDA margin before special items¹4 · Jun 2026
Cash flow-relevant capital expenditures2 · Jun 2026
EBIT of Enabling Functions and Consolidation2 · Jun 2026
Special items¹2 · Jun 2026
Special items of Enabling Functions and Consolidation2 · Jun 2026
Net cash provided by (used in) operating activities1 · Jun 2026

264 facts

Figures broken down by business line, region, product or another axis the company reports on.

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

14 calls · May 2023 to Aug 2026

Transcripts with management claims and analyst questions, one per fiscal period.

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.